Correction

Correction: Immunogenicity of mammary tumor cells can be induced by shikonin via direct binding-interference with hnRNPA1

Shu-Yi Yin[1], Thomas Efferth[2], Feng-Yin Jian[1], Yung-Hsiang Chen[1], Chia-I Liu[3], Andrew H.J. Wang[4], Yet-Ran Chen[1], Pei-Wen Hsiao[1] and Ning-Sun Yang[1]

[1] Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan, ROC

[2] Institute of Pharmacy and Biochemistry, University of Mainz, Germany

[3] School of Medical Laboratory Science and Biotechnology, Taipei Medical University, Taipei, Taiwan, ROC

[4] Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan, ROC

Published: *August 14, 2018*

This article has been corrected: An institutional investigation was conducted at the request of the Oncotarget editorial staff by the Academia Sinica Ethics Committee (Taipei, Taiwan). The Committee concluded the following: "The partial duplication of Figure 4a and 4b is judged to be a mistake during data processing, rather than a research misconduct." The correct Figure 4B is shown below; 4A appears correctly in the original article. The authors declare that these corrections do not change the results or conclusions of this paper.



Figure 4: hnRNPA1 is a critical mediator of the SK-induced ICD activity in mammary tumor cells. a. and **b.** Western blot analyses of expression of HSP70 and HMGB1 in human (MDA-MB-231) and mouse (4T1) tumor cells. Some 4T1, 4T1-hnRNPA1, MDA-MB-231 and MB-231-hnRNPA1 cells were treated with SK or Dox at 5 μg/ml for 24 h. β-actin was used as a loading control.

Original article: Oncotarget. 2016; 7:43629-43653. https://doi.org/10.18632/oncotarget.9660